Ann M Johnson
Overview
Explore the profile of Ann M Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carr D, Beyene K, Doherty J, Murphy S, Johnson A, Domash H, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2335651.
PMID: 37773496
Importance: Older adults are increasingly prescribed medications that have adverse effects. Prior studies have found a higher risk of motor vehicle crashes to be associated with certain medication use. Objective:...
2.
Babulal G, Chen L, Murphy S, Doherty J, Johnson A, Morris J
Am J Geriatr Psychiatry
. 2023 Aug;
31(12):1190-1199.
PMID: 37544835
Objectives: To investigate the effect of neuropsychiatric symptoms and depression symptoms, respectively, and Alzheimer disease (AD) biomarkers (cerebrospinal fluid [CSF] or Positron Emission Tomography [PET] imaging) on the progression to...
3.
Babulal G, Chen L, Carr D, Johnson A, Shimony J, Doherty J, et al.
J Neurol Sci
. 2023 Mar;
448():120616.
PMID: 36989588
Background: Cerebral small vessel disease (CSVD) as measured by cortical atrophy and white matter hyperintensities [leukoaraiosis], captured via magnetic resonance imaging (MRI) are increasing in prevalence due to the growth...
4.
Bayat S, Roe C, Schindler S, Murphy S, Doherty J, Johnson A, et al.
J Alzheimers Dis
. 2023 Mar;
92(4):1487-1497.
PMID: 36938737
Background: Driving behavior as a digital marker and recent developments in blood-based biomarkers show promise as a widespread solution for the early identification of Alzheimer's disease (AD). Objective: This study...
5.
Murphy S, Chen L, Doherty J, Acharyya P, Riley N, Johnson A, et al.
Front Psychol
. 2023 Jan;
13():1076735.
PMID: 36619039
Daily driving is a multi-faceted, real-world, behavioral measure of cognitive functioning requiring multiple cognitive domains working synergistically to complete this instrumental activity of daily living. As the global population of...
6.
Doherty J, Murphy S, Bayat S, Wisch J, Johnson A, Walker A, et al.
Alzheimers Dement
. 2022 Nov;
19(5):2014-2023.
PMID: 36419201
Introduction: We investigated the relationship between preclinical Alzheimer's disease (AD) biomarkers and adverse driving behaviors in a longitudinal analysis of naturalistic driving data. Methods: Naturalistic driving data collected using in-vehicle...
7.
Aschenbrenner A, Murphy S, Doherty J, Johnson A, Bayat S, Walker A, et al.
J Gerontol B Psychol Sci Soc Sci
. 2022 Jul;
77(10):1769-1778.
PMID: 35869666
Objectives: To determine the extent to which cognitive domain scores moderate change in driving behavior in cognitively healthy older adults using naturalistic (Global Positioning System-based) driving outcomes and to compare...
8.
Roe C, Bayet S, Hicks J, Johnson A, Murphy S, Doherty J, et al.
J Appl Gerontol
. 2022 May;
41(8):1831-1842.
PMID: 35543188
A thorough understanding of individual characteristics of older adults during the COVID-19 pandemic is critical for managing the ongoing pandemic course and planning for the future pandemics. Here, we explore...
9.
Wisch J, Roe C, Babulal G, Metcalf N, Johnson A, Murphy S, et al.
Sci Rep
. 2022 Apr;
12(1):6486.
PMID: 35443765
Our objective was to identify functional brain changes that associate with driving behaviors in older adults. Within a cohort of 64 cognitively normal adults (age 60+), we compared naturalistic driving...
10.
Doherty J, Roe C, Murphy S, Johnson A, Fleischer E, Toedebusch C, et al.
Sleep
. 2022 Mar;
45(6.
PMID: 35303111
Alzheimer's disease (AD) pathology accumulates for decades before the onset of cognitive decline. Cognitively normal individuals with biomarker evidence of AD brain pathology (i.e. biomarker + or preclinical AD) can...